CLRB — Cellectar Biosciences Share Price
0.000.00%
Last trade - 00:00- $19.04m
- $5.14m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.72 | ||
| Price to Tang. Book | 0.72 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -321.88% | ||
| Return on Equity | -622.62% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of drugs for treatment of cancer. The Company, through its phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its lead programs are: Iopofosine I 131 (iopofosine), a beta-emitting iodine-131-based program which has been studied extensively; CLR 121225, an actinium-225-based program; and CLR 121125, an iodine-125 Auger-emitting program. Iopofosine evaluation is ongoing in a Phase IIb study in r/r multiple myeloma and central nervous system lymphoma patients and the CLOVER-2 Phase Ib study for pediatric patients with high grade gliomas.
Directors
- Douglas Swirsky NEC (51)
- James Caruso PRE (62)
- Dov Elefant CFO (53)
- Jarrod Longcor OTH (48)
- Laurence Reilly OTH (39)
- Asher Alban Chanan-Khan DRC (52)
- Frederick Driscoll IND (71)
- Stefan Loren IND (57)
- John Neis IND (65)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- June 24th, 1996
- Public Since
- May 20th, 2005
- No. of Shareholders
- 100
- No. of Employees
- 11
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 46,079,875
- Address
- 100 Campus Drive, FLORHAM PARK, 07932
- Web
- https://www.cellectar.com/
- Phone
- +1 6084418120
- Auditors
- Deloitte & Touche LLP
Upcoming Events for CLRB
Cellectar Biosciences Inc Annual Shareholders Meeting
Q2 2025 Cellectar Biosciences Inc Earnings Release
Q3 2025 Cellectar Biosciences Inc Earnings Release
Similar to CLRB
60 Degrees Pharmaceuticals
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
Agriforce Growing Systems
NASDAQ Capital Market
Akari Therapeutics
NASDAQ Capital Market
Akebia Therapeutics
NASDAQ Capital Market
FAQ
What is the Cellectar Biosciences share price?
As of Today at 19:50 UTC, shares in Cellectar Biosciences are trading at $0.25. This share price information is delayed by 15 minutes.
How has the Cellectar Biosciences share price performed this year?
Shares in Cellectar Biosciences last closed at $0.25 and the price had moved by -92.64% over the past 365 days. In terms of relative price strength the Cellectar Biosciences share price has underperformed the S&P500 Index by -93.45% over the past year.
What are the analyst and broker recommendations for Cellectar Biosciences?
The overall consensus recommendation for Cellectar Biosciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Cellectar Biosciences dividend yield?
Cellectar Biosciences does not currently pay a dividend.
Does Cellectar Biosciences pay a dividend?
Cellectar Biosciences does not currently pay a dividend.
When does Cellectar Biosciences next pay dividends?
Cellectar Biosciences does not currently pay a dividend.
How do I buy Cellectar Biosciences shares?
To buy shares in Cellectar Biosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Cellectar Biosciences?
As of the previous close price of $0.25, shares in Cellectar Biosciences had a market capitalisation of $11.29m.
Where are Cellectar Biosciences shares listed?
Here are the trading details for Cellectar Biosciences:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: CLRB
What kind of share is Cellectar Biosciences?
Based on an overall assessment of its quality, value and momentum Cellectar Biosciences is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Cellectar Biosciences share price forecast for 2025?
The analyst consensus target price for shares in Cellectar Biosciences is $8.00. That is 3165.31% above the last closing price of $0.25.
Analysts covering Cellectar Biosciences currently have a consensus Earnings Per Share (EPS) forecast of -$0.60 for the next financial year.
Find out moreWhat is the trend in the Cellectar Biosciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cellectar Biosciences. Over the past six months, its share price has underperformed the S&P500 Index by -86.97%.
As of the last closing price of $0.25, shares in Cellectar Biosciences were trading -77.16% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Cellectar Biosciences PE Ratio?
The Cellectar Biosciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.25.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Cellectar Biosciences?
Cellectar Biosciences' management team is headed by:
- Douglas Swirsky - NEC
- James Caruso - PRE
- Dov Elefant - CFO
- Jarrod Longcor - OTH
- Laurence Reilly - OTH
- Asher Alban Chanan-Khan - DRC
- Frederick Driscoll - IND
- Stefan Loren - IND
- John Neis - IND